In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir

Abstract Ensitrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro or Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most omicron subvariants have reduced sensitivity to most monoclonal antibody therapies, SARS-CoV-2 resistance to othe...

Full description

Bibliographic Details
Main Authors: Maki Kiso, Seiya Yamayoshi, Shun Iida, Yuri Furusawa, Yuichiro Hirata, Ryuta Uraki, Masaki Imai, Tadaki Suzuki, Yoshihiro Kawaoka
Format: Article
Language:English
Published: Nature Portfolio 2023-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-40018-1

Internet

https://doi.org/10.1038/s41467-023-40018-1

Similar Items